Navigation Links
CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy
Date:5/11/2009

Non-adherent women up to six times more likely to experience a fracture

WOONSOCKET, R.I., May 11 /PRNewswire/ -- Data released today by CVS Caremark (NYSE: CVS) indicates that 87 percent of women 18 years and older with osteoporosis, who were taking a drug therapy to treat the disease, did not experience a fracture during the two-year study period. The CVS Caremark data also found that those women with osteoporosis between the ages of 18-64 who were not on therapy were 5.7 times more likely to experience a fracture.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO )

According to the National Osteoporosis Foundation (NOF), approximately eight million women in the U.S. have osteoporosis and an additional 27.2 million women are estimated to have low bone mass, which places them at increased risk for developing the disease. In addition, the NOF reports that one in two women with osteoporosis over the age of 50 will experience an osteoporosis related fracture in their remaining lifetime. The NOF also reports that in 2005, osteoporosis-related fractures were responsible for an estimated $19 billion in costs, which is predicted to increase to $25.3 billion by 2025.

"Osteoporosis impacts millions of women in the United States and the resulting fractures due to bone loss associated with the disease can have a significant impact on the individual's quality of life and increase overall health care costs for the patient and the payor," said Troyen Brennan, M.D., Chief Medical Officer, CVS Caremark. "Our research suggests that the medications available today to treat osteoporosis are effective in combating the disease and those women who take and remain adherent to therapy are better able to maintain their mobility and quality of life while avoiding costly fractures."

The study analyzed women diagnosed with osteoporosis over a two-year period. Untreated women less than 65 years of age were 5.7 times more likely to experience a fracture than those treated with a bisphosphonate, estrogen, or other hormone-related osteoporosis therapy. This study evaluated aggregated and de-identified data for almost 400,000 women from the CVS Caremark Health Management Claims Database who had incurred claims between 01/01/07 and 12/31/08. All study participants were continuously eligible for medical and pharmacy benefits throughout the evaluation period. This analysis is an observational study only, and the results demonstrate a relationship between osteoporosis, osteoporotic pharmacotherapy, and fractures; however, as in most observational studies, the causal nature of this relationship cannot be strictly determined.

"The National Osteoporosis Foundation emphasizes the importance of patient adherence and persistence to a prescribed treatment regimen in order to get the maximum benefit from a medication," said Robert Recker, M.D., president of the National Osteoporosis Foundation (NOF). "NOF is proud to sponsor National Osteoporosis Awareness and Prevention Month in May as an opportunity to raise awareness of this disease, help women understand their risk for developing osteoporosis and provide information about the treatments available today to help manage osteoporosis and reduce the risk of fracture."

About CVS Caremark

CVS Caremark is the largest provider of prescriptions in the nation. The Company fills or manages more than 1 billion prescriptions annually. Through its unmatched breadth of service offerings, CVS Caremark is transforming the delivery of health care services in the U.S. The Company is uniquely positioned to effectively manage costs and improve health care outcomes through its more than 6,900 CVS/pharmacy and Longs Drugs stores; its Caremark Pharmacy Services division (pharmacy benefit management, mail order and specialty pharmacy); its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations section of the Company's Web site, at www.cvscaremark.com/investors, as well as through the press room section of the Company's Web site, at www.cvscaremark.com/newsroom.

    Media Contact:
    Steve Campanini                                  Christine Cramer
    CVS Caremark                                     CVS Caremark
    Corporate Communications                         Corporate Communications
    (401) 770-5005                                   (401) 770-3317


'/>"/>
SOURCE CVS Caremark
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
2. Study Confirms: Your Hidden Food Allergies Are Making You Fat
3. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
4. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
5. Sosei Confirms the Safety of SD118 in Two Phase I Trials
6. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
7. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
8. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
9. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
10. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
11. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
Breaking Medicine Technology:
(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst ... third time to shed lights on the variety of topics detailing why we appreciate ... Appreciation” tackles why this career has gone from being in a major recession to ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought ... industry, from leading advocates, associations and industry leaders such as Bioness. , ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
(Date:5/27/2016)... ... ... With a team of certified experts, Validation Center is ... GMP accreditation, Validation Center is also a registered authority of the international system ... Validation Center is ISO17025 accredited and only offers its clients the latest technology, ...
Breaking Medicine News(10 mins):